XenoGesis, an acclaimed laboratory-based CRO, is now part of Sygnature Discovery, a leading provider of integrated drug discovery and non-clinical solutions. Founded in 2011, XenoGesis specializes in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, pharmacology, and expert interpretation. This strategic partnership with Sygnature Discovery, which took place in September 2020, has created an exceptional team of over 60 DMPK scientists.

Together with Sygnature's multidisciplinary teams, they offer a comprehensive and integrated drug discovery service to customers worldwide. We invite you to find us at our new home on sygnaturediscovery. com, where you will discover the full range of services you are familiar with from XenoGesis, as well as our complete suite of integrated drug discovery and non-clinical solutions.

With a mission to enhance our customers'​ research projects, Sygnature Discovery boasts a team of over 400 experienced research scientists, more than 80% of whom hold PhD qualifications. Our capabilities span medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, protein crystallography, and pre-clinical experimental services. Over the years, we have successfully delivered 37 compounds to pre-clinical development, with 17 progressing to clinical trials.

The XenoGesis team may now be reached at Sygnature Discovery, and we welcome the opportunity to collaborate and support your drug discovery projects. Contact us to speak with a scientist and elevate your research endeavors. With sites in Nottingham and Cheshire, UK, as well as an office presence in Boston, MA, USA, Sygnature Discovery is well-positioned to serve customers across the globe